Safety of an anti-PD-1 immune checkpoint inhibitor in a liver transplant recipient

Monoclonal antibodies directed against regulatory immune checkpoint molecules that inhibit T-cell activation have demonstrated great efficacy in the treatment of metastatic cancer, enhancing the antitumor immunity.